CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Docetaxel and Hormone Treatment compared to Hormone Treatment alone in people with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response (TRIPLE-SWITCH)
From the Director’s Desk
September still feels like the beginning of a new year to me.
First results from the CCTG PR13 RADICALS: Radiotherapy and Androgen Deprivation In Combination After Local Surgery were presented at the European Society for Medical Oncology (ESMO) 2022 annual congress in Paris France on September 12.
CO28: NEOadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer: The NEO Trial
Recently published in the Journal of Clinical Oncology
Hilary Horlock is a Senior Enterprise Architect. She specializes in healthcare technology design from an end user perspective. Implementing technology successfully in complex health care ecosystems often comprised of large personalities and competing demands takes expert navigation skills, liberal doses of good humor, a keen sense of observation and refreshing honesty.
The CO26 sub-study: Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer has recently been published in Journal of Clinical Oncology.
The Canadian Cancer Trials Group (CCTG) Operations and Statistics Centre will receive full funding of $19,457,683 through The Major Science Initiatives (MSI) Fund. Minister of Innovation, Science and Industry, François-Philippe Champagne announced the award at Queen’s University as part of the 19 successful research infrastructure projects receiving $628 million from the Canada Foundation for Innovation (CFI).
